Results · Apr-Jun 2026
Rekvina Laboratories Q1 FY27 results
Sales were ₹0.67 crore against ₹0 crore in Apr-Jun 2025.
Operating profit was −₹0.12 crore, an operating margin of −18.0%.
The net loss widened to ₹0.12 crore from ₹0.04 crore.
Against Jan-Mar 2026: sales −8%, loss widens.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 0.7 | 0.0 | n/m |
| Operating profit (EBITDA) | -0.1 | -0.0 | n/m |
| Operating margin | −18.0% | - | - |
| Net profit | -0.1 | -0.0 | loss widens |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.